Clinical trials: Patients With Prostate Cancer
- Condition Patients With Prostate Cancer
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Metastatic Prostate Cancer
64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)
This is a Phase 1 trial of TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592).
- Trial name
- CUPID (NCT04726033)
- Testing
- 64Cu-DOTA-TLX592
- Where
- 2 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Castration-resistant Prostate Cancer
Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone
In this observational study researchers want to gather more information about safety and survival in patients suffering from castration-resistant prostate cancer (CRPC) which has spread to the bone and were treated with…
- Trial name
- RAPIT (NCT04232761)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- Taiwan
- Volunteers
- 194 people
- Sponsor
- Bayer
Venous Thromboembolism (VTE)
Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners
Patients with cancer are at a significantly increased risk of experiencing a venous thromboembolism (VTE). VTE is defined by a blood clot in the leg or lower extremity (deep vein thrombosis) or a blood clot in the lung (pulmonary…
- Trial name
- PRACTISE (NCT03965741)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban(Eliquis), Pradaxa (Dabigatran etexilate)
- Where
- Sweden
- Volunteers
- 97,765 people
- Sponsor
- Bayer
Prostate Cancer
A Study Into the Effectivity and Safety of Firmagon, Prescribed for Treatment of Patients With Advanced Prostate Cancer
Patients eligible for hormone ablation therapy who are prescribed Firmagon will be followed for a maximum of 3 years to estimate the progression free survival.
- Trial name
- FAST-NL (NCT01215526)
- Where
- 47 sites in Netherlands
- Volunteers
- 274 people
- Sponsor
- Ferring Pharmaceuticals
Prostatic Neoplasms
Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients
Primary Objective: Describe real-life survival of CRPC patients who received first-line docetaxel and have disease progression Secondary Objective: Describe treatment patterns Describe the characteristics and outcomes of patients…
- Trial name
- PORTREAT (NCT01076751)
- Where
- 5 sites in United States, France and 3 more
- Volunteers
- 82 people
- Sponsor
- Sanofi
Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
The objective of this study was to evaluate the incidence of seizures and monitor the safety of enzalutamide treatment in participants with metastatic castration-resistant prostate cancer (mCRPC) known to have risk factor(s) for…
- Trial name
- UPWARD (NCT01977651)
- Testing
- Enzalutamide
- Where
- 76 sites in United States, Argentina and 18 more
- Volunteers
- 424 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Prostate Cancer
A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON
This study is a large observational study, set-up to observe how long-term treatment with FIRMAGON (hormone regulator) compare to other treatments in regards to cardiovascular events, changes in bone density, changes in blood…
- Trial name
- NCT01234350
- Where
- 160 sites in Belgium, Denmark and 13 more
- Volunteers
- 1,493 people
- Sponsor
- Ferring Pharmaceuticals
Prostatic Neoplasms
A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer
The aim of this study was to evaluate the efficacy of two different doses of BIBF 1120 (250 mg twice daily versus 150 mg twice daily) in an exploratory manner.
- Trial name
- NCT02182063
- Testing
- BIBF 1120 low dose, BIBF 1120 high dose
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
In this study researcher want to learn more about the overall survival in patients suffering from prostate gland cancer which spread outside the prostate to other parts of the body who received either a novel anti-hormone therapy…
- Trial name
- PHENIX (NCT03896984)
- Testing
- Radium-223 (Xofigo, BAY88-8223), Abiraterone, Enzalutamide
- Where
- United States
- Volunteers
- 346 people
- Sponsor
- Bayer
Hypereosinophilic Syndrome, Systemic Mastocytosis
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
This trial is for various types of malignancies which may depend on certain enzymes (tyrosine kinases) for growth. The objective of this study is to assess to what extent imatinib mesylate blocks these enzymes and to assess the…
- Conditions
- Hypereosinophilic Syndrome, Systemic Mastocytosis, Chronic Myelomonocytic Leukemia, Dermatofibrosarcoma
- Trial name
- NCT00171912
- Testing
- imatinib mesylate
- Where
- Australia
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
The primary purpose of this study is to evaluate the efficacy of triptorelin embonate 22.5 mg 6-month formulation administered by the subcutaneous (under the skin) route in: achieving castrate levels of testosterone (< 1.735…
- Trial name
- NCT01656161
- Testing
- Triptorelin embonate 22.5 mg
- Where
- 10 sites in South Africa
- Volunteers
- 120 people
- Sponsor
- Debiopharm International SA
Prostate Cancer
Observational Retrospective Trial on Sequential Hormonal Therapy in Patients With Prostate Cancer
Observational Retrospective trial on sequential hormonal therapy in patients with Prostate Cancer
- Trial name
- Sorse (NCT00668083)
- Where
- 12 sites in Italy
- Volunteers
- 214 people
- Sponsor
- AstraZeneca
Metastatic Castration-Resistant Prostate Cancer
Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
The purpose of this treatment protocol is to provide expanded access to MDV3100 and monitor its safety in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.
- Trial name
- NCT01606982
- Testing
- MDV3100
- Sponsor
- Astellas Pharma Global Development, Inc.
Advanced Prostate Cancer
A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.
This is A Multi-centre, Single-arm, Prospective, Interventional Study to Assess Efficacy and Safety of Neoadjuvant Hormone Therapy using Zoladex (Goserelin) and Casodex (Bicalutamide) in Patients with Advanced Prostate Cancer…
- Trial name
- NCT03971110
- Testing
- Zoladex and Casodex
- Where
- 15 sites in China
- Volunteers
- 9 people
- Sponsor
- AstraZeneca
Prostate Carcinoma
Evaluation of QoL, Tolerability and Use of Zoladex 10,8 SafeSystem for Advanced PCa - German IPEP Trial
Purpose of this study is the evaluation of QoL, tolerability and use of Zoladex 10,8 SafeSystem for advanced PCa under naturalistic conditions
- Trial name
- NCT00540059
- Volunteers
- 1,950 people
- Sponsor
- AstraZeneca
Prostatic Neoplasms
Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer
The purpose of this study is to investigate the safety, tolerability and anti-tumor effects of treatment with samarium Sm-153 lexidronam in combination with docetaxel in patients with castrate metastatic prostate cancer.
- Trial name
- NCT00121095
- Testing
- Samarium Sm-153 lexidronam + Docetaxel
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Cytogen Corporation
Prostatic Neoplasm
Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer
Efficacy and safety of a triptorelin 6-month formulation in patients with advanced prostate cancer. It was assumed that during the study treatment >90% of the patients would achieve and maintain castrate levels of serum…
- Trial name
- NCT00751790
- Testing
- triptorelin embonate (INN)
- Where
- South Africa
- Volunteers
- 120 people
- Sponsor
- Debiopharm International SA
Prostate Cancer
Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.
The purpose of the protocol, is to assess the feasibility of conducting a larger trial to evaluate the effect of a psychological intervention on the well-being of patients on luteinizing hormone-releasing hormone (LHRH) analogs…
- Trial name
- EXPEDIENT (NCT01562522)
- Testing
- Psychological counseling
- Where
- 3 sites in Netherlands
- Volunteers
- 6 people
- Sponsor
- Ipsen
Colorectal Neoplasms, Lung Neoplasms
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
This is a Phase 1 study investigating the safety and tolerability of Figitumumab plus Pegvisomant for treatment of advanced solid tumors.
- Conditions
- Colorectal Neoplasms, Lung Neoplasms, Breast Neoplasms, Prostatic Neoplasms
- Trial name
- NCT00976508
- Testing
- figitumumab, pegvisomant
- Where
- 5 sites in United States, Canada and 2 more
- Volunteers
- 24 people
- Sponsor
- Pfizer